---
title: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285778914.md"
description: "PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported its 1Q 2026 results, showing revenue of $37.18M, nearly unchanged from the previous year. The company narrowed its loss, with diluted EPS at ($0.03) compared to ($1.44) a year ago. Gross profit improved to $12.8M, aided by reduced costs and a favorable product mix. The company also completed an asset sale to Illumina for $48.1M and is advancing its product pipeline with new launches planned for 2027."
datetime: "2026-05-08T21:31:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285778914.md)
  - [en](https://longbridge.com/en/news/285778914.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285778914.md)
generator: "portal-rs"
---

# PACIFIC BIOSCIENCES OF CALIFORNIA, INC. 1Q 2026: Revenue $37.18M, EPS ($0.03) — 10-Q Summary

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported first-quarter 2026 results with revenue essentially flat year over year at $37.18M and a narrowed loss; diluted EPS was ($0.03) compared with ($1.44) in the year-ago quarter.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

$37.18M

$37.15M

0.1%

Net income²

($8.28M)

($426.08M)

98.1%

Diluted EPS³

($0.03)

($1.44)

97.9%

*¹ Reported as “Total revenue”. ² Reported as “Net loss”. ³ Reported as “loss per share”.*

**Business Highlights**

-   Total revenue was essentially unchanged at $37.2M as growth in consumables and Revio placements offset lower Vega instrument sales.
-   Gross profit turned positive to $12.8M from a $1.4M loss a year earlier, helped by lower cost of revenue and a favorable consumables mix.
-   R&D and SG&A expense reductions of about 33% and 22% year over year improved operating losses following workforce and program trims.
-   Completed an asset sale to Illumina, netting approximately $48.1M in proceeds, and entered a PGI settlement and licensing arrangement with staged payments.
-   Product pipeline and commercialization plans include the SPRQ‑Nx launch, Basecamp Research rollouts to drive consumable adoption, and a high-throughput HiFi sequencer targeted for 2027.

Original SEC Filing: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. \[ PACB \] - 10-Q - May. 08, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [PACB.US](https://longbridge.com/en/quote/PACB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [ILMN.US](https://longbridge.com/en/quote/ILMN.US.md)

## Related News & Research

- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [09:28 ETNew LabCentral Program "The Loop" Offers International Biotech Start-Ups and Partner Organizations Curated Learnings Directly from U.S. Market](https://longbridge.com/en/news/298328140.md)
- [PacBio Cuts Outlook as SPRQ-Nx Transition Slows, Targets 2028 Cash-Flow Positivity](https://longbridge.com/en/news/296015220.md)
- [Full Transcript: Cellectar Biosciences Q1 2026 Earnings Call](https://longbridge.com/en/news/286422585.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**